Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Rosacea Clear all
Completed Phase 4 Interventional Results available

Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea

NCT00855595
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
17
States / cities
Birmingham, Alabama • Denver, Colorado • West Palm Beach, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 21 Day Pharmacokinetics Study in Papulopustular Rosacea

NCT02028286
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
CLS001
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
2
States / cities
Hackensack, New Jersey • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea

NCT02144181
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Rosacea
Interventions
Ulthera System Treatment
Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Omaha, Nebraska • Wilmington, North Carolina • Hummelstown, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Rosacea and Ivermectin

NCT04275999
View directory record Official record
Conditions
Rosacea
Interventions
ivermectin, digital interaction, GPSkin
Drug · Behavioral · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 3 Interventional

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

NCT02393937
View directory record Official record
Conditions
Papulopustular Rosacea, Erythematotelangiectatic Rosacea
Interventions
Reference: Metronidazole Gel 1%, Test: Metronidazole Gel 1%, Placebo Gel
Drug
Lead sponsor
bioRASI, LLC
Industry
Eligibility
18 Years and older
Enrollment
963 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
27
States / cities
Los Angeles, California • San Diego, California • Boca Raton, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Jul 22, 2026, 5:06 PM EDT
Active, not recruiting Phase 4 Interventional

Ocular Rosacea Biome Study

NCT05296837
View directory record Official record
Conditions
Ocular Rosacea, Antimicrobial Resistance
Interventions
Doxycycline 40 MG ( 20mg twice daily), Doxycycline 200 MG ( 100 mg twice daily), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01494467
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

NCT03564119
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
S5G4T-1, S5G4T-2
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01174030
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 Gel, Vehicle Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Hot Springs, Arkansas • San Francisco, California • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

NCT03590366
View directory record Official record
Conditions
Rosacea
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Clearwater, Florida • Miami, Florida • Miramar, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

NCT03263273
View directory record Official record
Conditions
Rosacea, Papulopustular Rosacea
Interventions
1% Topical Minocycline Gel, 3% Topical Minocycline Gel, Topical Vehicle Gel
Drug · Other
Lead sponsor
Hovione Scientia Limited
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
23
States / cities
Bryant, Arkansas • Rogers, Arkansas • Fremont, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Pilot Study on the Use of Seysara for Rosacea

NCT04555525
View directory record Official record
Conditions
Acne Rosacea
Interventions
sarecycline, Centrum Adult Multivitamin
Drug · Dietary Supplement
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591
View directory record Official record
Conditions
Erythemato-telangiectatic Rosacea
Interventions
BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea

NCT04153188
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
The Vbeam® Prima System, Oxymetazoline HCL 1% Cream
Device · Drug
Lead sponsor
Candela Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

ORCA - Oracea® for Rosacea: A Community-based Assessment

NCT00892281
View directory record Official record
Conditions
Rosacea
Interventions
doxycycline (Oracea®) 40 mg modified release as monotherapy, doxycycline (Oracea®) 40 mg modified release as add-on therapy
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
1,421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Jul 22, 2026, 5:06 PM EDT
Completed No phase listed Observational Results available

Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale

NCT01636765
View directory record Official record
Conditions
Erythema, Rosacea
Interventions
No Intervention
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo

NCT01308619
View directory record Official record
Conditions
Rosacea
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Hot Springs, Arkansas • San Diego, California • Evansville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Jul 22, 2026, 5:06 PM EDT
Enrolling by invitation Phase 2 Interventional

Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

NCT07443202
View directory record Official record
Conditions
Ocular Rosacea
Interventions
lotilaner, Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Houston, Texas • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face

NCT02800148
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam, Azelaic acid foam - Placebo
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
667 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 1 Interventional

Topical Agent for Treatment of Red Skin

NCT00279890
View directory record Official record
Conditions
Rosacea, Bilaterally Symmetric Red Skin on Cheeks
Interventions
Topical SR-01
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated May 22, 2011 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

NCT01025635
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam 15%, Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Fremont, California • Santa Monica, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 22, 2026, 5:06 PM EDT
Not listed Not applicable Interventional

Using a Cold Atmospheric Plasma Device to Treat Skin Disorders

NCT02759900
View directory record Official record
Conditions
Actinic Keratosis, Acne/Rosacea, Verruca Plana, Tinea, Molluscum Contagiosum, Bowen's Disease, Warts
Interventions
Non-thermal, atmospheric plasma to treat skin lesions and acne, Indirect non-thermal, atmospheric plasma to treat hair loss and acne
Device
Lead sponsor
The Skin Center Dermatology Group
Industry
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
New City, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Jul 22, 2026, 5:06 PM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea

NCT00989014
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea
Interventions
CD07805/47, CD07805/47 placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
5
States / cities
Hot Springs, Arkansas • Fort Washington, Pennsylvania • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 5:06 PM EDT